WO2001016355A3 - In vitro test system for gamma-secretase from enriched membranes - Google Patents

In vitro test system for gamma-secretase from enriched membranes Download PDF

Info

Publication number
WO2001016355A3
WO2001016355A3 PCT/EP2000/008340 EP0008340W WO0116355A3 WO 2001016355 A3 WO2001016355 A3 WO 2001016355A3 EP 0008340 W EP0008340 W EP 0008340W WO 0116355 A3 WO0116355 A3 WO 0116355A3
Authority
WO
WIPO (PCT)
Prior art keywords
secretase
gamma
test system
vitro test
substances
Prior art date
Application number
PCT/EP2000/008340
Other languages
German (de)
French (fr)
Other versions
WO2001016355A2 (en
Inventor
Katja Fechteler
Klaus Fuchs
Marcus Kostka
Original Assignee
Boehringer Ingelheim Pharma
Katja Fechteler
Klaus Fuchs
Marcus Kostka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Katja Fechteler, Klaus Fuchs, Marcus Kostka filed Critical Boehringer Ingelheim Pharma
Priority to MXPA02001754A priority Critical patent/MXPA02001754A/en
Priority to JP2001520900A priority patent/JP2003508058A/en
Priority to EP00962393A priority patent/EP1212454A2/en
Priority to CA002381952A priority patent/CA2381952A1/en
Publication of WO2001016355A2 publication Critical patent/WO2001016355A2/en
Publication of WO2001016355A3 publication Critical patent/WO2001016355A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The invention relates to a method for identifying specific η-secretase inhibitors which can be used for treating neuro-degenerative diseases, in particular to a method which can be carried out in vitro. The invention also relates to a test kit which can be used for said method, in addition to the use of this test kit or method to identify substances which specifically inhibit η-secretase. A further embodiment relates to the use of these substances to produce a medicament for treating neuro-degenerative diseases and to pharmaceutical formulations which contain said substances.
PCT/EP2000/008340 1999-08-28 2000-08-25 In vitro test system for gamma-secretase from enriched membranes WO2001016355A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MXPA02001754A MXPA02001754A (en) 1999-08-28 2000-08-25 In vitro test system for gamma secretase from enriched membranes.
JP2001520900A JP2003508058A (en) 1999-08-28 2000-08-25 γ-secretase in vitro test system
EP00962393A EP1212454A2 (en) 1999-08-28 2000-08-25 In vitro test system for gamma-secretase from enriched membranes
CA002381952A CA2381952A1 (en) 1999-08-28 2000-08-25 .gamma.-secretase in vitro test system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999141039 DE19941039A1 (en) 1999-08-28 1999-08-28 gamma-secretase in vitro test system
DE19941039.9 1999-08-28

Publications (2)

Publication Number Publication Date
WO2001016355A2 WO2001016355A2 (en) 2001-03-08
WO2001016355A3 true WO2001016355A3 (en) 2001-08-30

Family

ID=7920037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/008340 WO2001016355A2 (en) 1999-08-28 2000-08-25 In vitro test system for gamma-secretase from enriched membranes

Country Status (6)

Country Link
EP (1) EP1212454A2 (en)
JP (1) JP2003508058A (en)
CA (1) CA2381952A1 (en)
DE (1) DE19941039A1 (en)
MX (1) MXPA02001754A (en)
WO (1) WO2001016355A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10000161A1 (en) * 2000-01-06 2001-07-19 Boehringer Ingelheim Pharma Determining test substances that inhibit protease, involves incubating cells expressing fusion protein having substrate with cleavage site for protease and reporter, measuring cleaved reporter and comparing with standard
EP1305634A2 (en) 2000-04-03 2003-05-02 Bristol-Myers Squibb Company Fluorescence assay for gamma-secretase activity and inhibitors
EP1305406B2 (en) 2000-05-11 2014-11-12 Scios Inc. Modulation of gamma-secretase activity
DE10131899A1 (en) * 2001-07-04 2003-02-27 Boehringer Ingelheim Pharma In Vitro Screening Assay for Gamma Secretase
WO2005031363A1 (en) * 2003-09-24 2005-04-07 University Of Chicago Membrane preparation from pichia pastoris to assay ϝ-secretase activity
CN1925869A (en) * 2004-01-29 2007-03-07 塞尔卓姆股份公司 Treatment of neurodegenerative diseases by the use of GPR49
ES2300852T3 (en) * 2004-01-29 2008-06-16 Cellzome Ag TREATMENT OF NEUROGENERATIVE DISEASES THROUGH THE USE OF GPR49.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0778266A1 (en) * 1995-12-05 1997-06-11 Bristol-Myers Squibb Company 5-Amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of beta-amyloid protein production
WO1997028261A1 (en) * 1996-01-31 1997-08-07 The Regents Of The University Of California Tandem fluorescent protein constructs
WO1997041443A2 (en) * 1996-04-26 1997-11-06 Smithkline Beecham Plc Method for screening compounds
WO1998015828A1 (en) * 1996-10-07 1998-04-16 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11507538A (en) * 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β-secretase, antibodies to β-secretase, and assays for detecting β-secretase inhibition
DE19641180A1 (en) * 1996-09-24 1998-03-26 Schering Ag A method of displaying APP secretase modulation and its use as an agent for the treatment of Alzheimer's disease
WO1998021589A1 (en) * 1996-11-15 1998-05-22 The Trustees Of The University Of Pennsylvania Screening for modulators of amyloid processing

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0778266A1 (en) * 1995-12-05 1997-06-11 Bristol-Myers Squibb Company 5-Amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of beta-amyloid protein production
WO1997028261A1 (en) * 1996-01-31 1997-08-07 The Regents Of The University Of California Tandem fluorescent protein constructs
WO1997041443A2 (en) * 1996-04-26 1997-11-06 Smithkline Beecham Plc Method for screening compounds
WO1998015828A1 (en) * 1996-10-07 1998-04-16 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KUENTZEL SANDRA L ET AL: "The Alzheimer beta-amyloid protein precursor/protease nexin-II is cleaved by secretase in a trans-Golgi secretory compartment in human neuroglioma cells.", BIOCHEMICAL JOURNAL, vol. 295, no. 2, 1993, pages 367 - 378, XP000986602, ISSN: 0264-6021 *
LI YUE-MING ET AL: "Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 11, 23 May 2000 (2000-05-23), May 23, 2000, pages 6138 - 6143, XP002159974, ISSN: 0027-8424 *
SHOJI M ET AL: "PRODUCTION OF THE ALZHEIMER AMYLOID BETA PROTEIN BY NORMAL PROTEOLYTIC PROCESSING", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 258, 2 October 1992 (1992-10-02), pages 126 - 129, XP000616170, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
DE19941039A1 (en) 2001-03-01
CA2381952A1 (en) 2001-03-08
WO2001016355A2 (en) 2001-03-08
JP2003508058A (en) 2003-03-04
EP1212454A2 (en) 2002-06-12
MXPA02001754A (en) 2002-10-23

Similar Documents

Publication Publication Date Title
EP1140840A4 (en) -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IS2156B (en) Placed benzenesulfonamide derivatives as prodrugs for COX-2 inhibitors, their preparation method, pharmaceutical compositions containing them and their use in the manufacture of drugs
EP1449834A3 (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
CA2359510A1 (en) .omega.-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE221531T1 (en) CRYSTAL MODIFICATION OF CDCH, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME
DE69811735T2 (en) HETEROCYCLIC COMPOUNDS FOR INHIBITING PELLETIC ACID PRODUCTION, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS THEREOF
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
HUP0301281A2 (en) New pharmaceutical composition
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
AU4710499A (en) Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use ofsuch compounds
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
PL374443A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2004047792A3 (en) Liposomal glucocorticoids
WO2001074839A3 (en) Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha, 11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use
TW268937B (en)
DE69725860D1 (en) PLAN FOR ADMINISTRATION OF H +, K + -ATPase INHIBITORS
DE60301570D1 (en) 1,2,3-SUBSTITUTED INDOLICIDE DERIVATIVES, FGF INHIBITORS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THEREOF
ZA965969B (en) Salts derived from amidine and cyclooxygenase inhibitor process for the preparation thereof their application as medicinal drugs and pharmaceutical compositions in which they are contained
SE9603725D0 (en) New teatment
WO2001016355A3 (en) In vitro test system for gamma-secretase from enriched membranes
DE60100500D1 (en) SUSPENSION CONTAINING AN EPI-HNE PROTEIN, METHOD FOR THE PRODUCTION THEREOF, DRY POWDER AEROSOL MADE THEREOF, MEDICINAL COMPOSITIONS CONTAINING THIS SUSPENSION OR THIS AEROSOL AND THEIR USE
WO2005002500A3 (en) Inhibitors of coronavirus
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use
DE59708495D1 (en) SOLID INSTANT RELEASE PHARMACEUTICAL FORMS AND METHOD FOR THEIR PRODUCTION

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2000962393

Country of ref document: EP

Ref document number: 2381952

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001754

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2001 520900

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10069801

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000962393

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000962393

Country of ref document: EP